Process for removing adventitious agents during the production of a virus in cell culture
AssigneeGlaxosmithkline Biologicals SA
InventorsFrancoise Marie Isabelle Collignon, Isabelle Solange Lucie Knott, Jean-Philippe Jules Jeanine Matheise
Life of this patent
Estimating the term…
Abstract
The present invention relates to improved processes for the production of viruses, in particular, viruses for use in medicine (for example vaccination or gene therapy).
Claims37
A process for producing a virus of interest in cell culture, comprising contacting a population of cells with a solution comprising the virus of interest, wherein the cells are susceptible to infection with the virus of interest, characterised in that the contact time between the solution comprising the virus of interest and susceptible cells is inferior than or equal to 120 minutes.
A process for producing a virus of interest comprising the steps of:
- a) contacting a population of cells with a solution comprising the virus of interest for a period inferior than or equal to about 120 minutes, wherein the cells are susceptible to infection with the virus of interest;
- b) removing the solution comprising the virus of interest from the cells, and
- c) incubating the cells in a culture medium to produce a population of replicated virus of interest.
A process for producing a virus of interest comprising the steps of:
- a) contacting a population of cells with an initial solution comprising the virus of interest and at least one adventitious agent, wherein the cells are susceptible to infection with the virus of interest and the contact period of time is sufficient to permit infection of at least a subset of the population of cells with the virus of interest,
- b) removing the solution comprising the virus of interest and the at least one adventitious agent from the cells,
- c) incubating the cells in a culture medium to produce a population of replicated virus of interest,
- wherein the DNA content level of the at least one adventitious agent is reduced by at least 90% in the population of replicated virus of interest as compared to the level present in the initial solution comprising the virus of interest and the at least one adventitious agent.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.